- Study protocol
- Open Access
- Open Peer Review
The efficacy and safety of probiotics intervention in preventing conversion of impaired glucose tolerance to diabetes: study protocol for a randomized, double-blinded, placebo controlled trial of the Probiotics Prevention Diabetes Programme (PPDP)
BMC Endocrine Disordersvolume 15, Article number: 74 (2015)
Alterations in intestinal microbiota correlate with risk of development of obesity and type 2 diabetes. Probiotics have been suggested to play an important role in the management of dysglycemia, although the evidence is limited. In this study, we aim to explore the efficacy and safety of probiotics intervention in preventing type 2 diabetes in Chinese patients with impaired glucose tolerance.
A 24-month randomized intervention is conducted from January 2014 to December 2016. The target sample size for intervention is 200 middle-aged men and women aged 30–65 year-old with impaired glucose tolerance. Participants with persistent impaired glucose tolerance were assigned to group A (tablet A) and B (tablet B) in sequential order. The participants and investigators were blinded to the assignment. The primary outcome is development of diabetes. The secondary outcome measures include body composition, biochemical variables and the safety of the probiotics.
The results from this trial will provide the evidence on the efficacy and safety of probiotics administration in preventing conversion of impaired glucose tolerance to diabetes in a Chinese context.
Diabetes has become a worldwide epidemic in the general population. In China, the prevalence of diabetes among adults is 11.6 % according to the data released in 2013 . In addition, the prevalence of prediabetes is up to 50.1 %. Individuals with prediabetes, especially impaired glucose tolerance (IGT), are at higher risk of developing type 2 diabetes, compared with individuals with normal glucose tolerance.
Studies have shown that early intervention in patients with IGT can significantly reduce the number of those patients who subsequently develop type 2 diabetes [2–6]. Those effective interventions conclude lifestyle modification and drug therapy. The efficacy of lifestyle modification in preventing the conversion of IGT to type 2 diabetes is proven [2, 3]. Drug therapy such as metformin, alpha-glucosidase inhibitor and Thiazolidinediones, has also been proven useful in the primary prevention of diabetes in people with IGT [4–9]. However, in clinical practice, the compliance of using hypoglycemic drugs to reduce the incidence of diabetes for nondaibetic subjects in natural population is relatively low. So to find a kind of non-hypoglycemic agents, on the basis of lifestyle modification, to help preventing the conversion of IGT to diabetes for subjects with prediabetes will be meaningful.
Recent evidences suggest that alterations in gut microbiota play an important role in the pathogenesis of obesity-related disorders, including diabetes and non-alcoholic fatty liver disease [10–15]. Compared with germ-free mice, conventionally raised mice were more prone to obesity and insulin resistance . In human studies, it also has shown that gut microbiota composition differs between obese and lean subjects . Recent metagenome-wide association studies showed that patients with type 2 diabetes have an increase in the abundance of Lactobacillus species and decreases in the abundance of Clostridium species [12, 13]. Thus, reshaping the gut microbiome may be a new direction for the prevention and treatment of diabetes in human beings. Currently the published evidences of the treatment of metabolic diseases with probiotics are limited, and the results are inconsistent [16–19]. Some but not all trials suggest that probiotics consumption may improve blood glucose level and antioxidant status in type 2 diabetic patients . Two trials showed that probiotics intervention only improved the lipid metabolism but not blood glucose in patients with diabetes or gestational diabetes mellitus [17, 18]. Only one trial explored the effects of probiotics administration on the outcomes of blood lipids and blood pressure in patients with prediabetes, but no data on the outcome of glucose metabolism . In addition, the intervention period of those trials may be too short (4 to 8 weeks) to observe the effect of probiotics. To date there is no clinical trial to explore whether probiotics administration can reduce the risk of development of type 2 diabetes in patients with prediabetes.
Therefore, the purpose of this study is to investigate the efficacy and safety of probiotics administration in preventing the development of type 2 diabetes in subjects with IGT compared to placebo. In addition, we will determine probiotics administration improve insulin sensitive and metabolic variables. The secondary outcome measures include body composition, biochemical variables and the safety of probiotics.
The PPDP is a 24-month, double-blinded, two-arm parallel group trial. Participants are individually randomized to one of two intervention groups in a 1:1 allocation. Participants are recruited from the outpatient department of five clinical centers in Shanghai during 2014 to 2016. They are Shanghai East Hospital, Shanghai Fifth People’s Hospital, Xinhua Hospital, Chongming Branch, Shanghai Pudong Hospital, Shanghai Seventh People’s Hospital. After an initial screening, potential subjects will be assessed for inclusion in the run-in trial. Those who meet the inclusion criteria are randomized to either intervention group or placebo group (Fig. 1).
Inclusion criteria are : (i) men or women aged 30–65 years; (ii) diagnose IGT after oral glucose tolerance test (OGTT) according to 1999 WHO criteria (fasting glucose <6.1 mmol/L, and 2-h post glucose load ≥ 7.8 and <11.1 mmol/L), (iii) no chronic cardiovascular, liver, kidney, lung diseases, (iv) informed consent, agreement on no other drug therapy on IGT during trial.
Exclusion criteria are : (i) patients with severe liver, kidney, heart, nervous system and gastrointestinal diseases, (ii) diagnosis of diabetes mellitus, (iii) allergy to studied agents, (iv) suspected or definite a history of alcohol or drug abuse history, (v) the possibility of loss to follow-up according to the judgment of the researchers, (vi) patients who have participated in other clinical trials in the past 3 months.
Eligible participants are randomly assigned in double-blind to receive either probiotics or placebo which are blinded as Tablet A and Tablet B for 24 months. The key that indentifies the subjects and which group they belong to is kept by a third party, and is not revealed to the researchers until the end of the study and the statistic analysis is finished. Probiotics are provided by Bifico (Approval number: S10950032), an over the counter capsule consists of live combined Bifidobacterium longum [National Center for Medical Culture Collections (CMCC): P0001], Lactobacillus acidophilus [CMCC: P0002] and Enterococcus faecalis [CMCC: P0003] produced by Shanghai Sine Pharmaceutical Laboratories Co,Ltd. The study drug and the placebo are prepared in indistinguishable tablets. For both group, the dose are 840 mg daily, 210 mg per one pill, two pills per time, two times daily (Fig. 1).
The primary clinical outcome is the improvement of risk of developing diabetes after administration of probiotics for 24 months.
(i) the cumulative prevalence of diabetes in the two groups, (ii) the changes of blood glucose, lipid profile and insulin sensitivity in the two groups, (iii) the changes of body weight and waist circumference, (iv) the safety assessment of probiotics, (v) the change of the abundance of gut bacteria, (vi) the change of blood lipopolysaccharides (LPS) and GLP-1 levels.
The purpose of the screening is to verify the eligibility of potential participants selected from the Department of Outpatient. The recruitment of participants will be done in the Department of Endocrinology of Shanghai East Hospital, Shanghai, China. Every potential participant will be informed the detailed information of the objectives of the study, the participated risks and the expected benefits. When the concert form has been signed, participants will be asked to fill a standardized questionnaire about medical history and to undergo a 75 g OGTT, insulin release test, liver and kidney function test (blood draw after 8 h overnight fasting and 30 min and 2 h after glucose load).
Before the first visit, a physician examines all the results of the screening to verify whether the subject meets the inclusion criteria. In the first visit (within 1 week of the screening), if a person is qualified for participation in the study (fasting glucose <6.1 mmol/L, and 2-h post glucose load ≥7.8 and <11.1 mmol/L, with no other chronic diseases), he or she will be invited to the clinical laboratory of Department of Endocrinology, Shanghai East Hospital for height, weight, waist circumference and blood pressure measurement, as well as instructions for fecal sample. Then they will be randomized and assigned in double-blind to receive either probiotics or placebo for 8 weeks. We emphasize the importance of their participation in study and instruct them to take medicine on time during the intervention.
The purpose of follow-up visits is to monitor the compliance and to discover the adverse events. After the first visit, a researcher will contact participants every month to check their medication. The participants will have follow-up visits to the clinical laboratory every 2 months. Their height, weight, waist circumference, hip circumference, blood pressure, heart rate and newly combined medication will be checked at those time points. In addition, at months 6, 12, 18, 24, participants will undergo a 75 g OGTT to evaluate the glycemic status (blood draw after 8 h overnight fasting and 30 min and 2 h after glucose load) and take blood samples and fecal samples (Table 1).
Methods of measurements
Height and weight will be measured with light clothes and without shoes. Waist circumference will be measured at the level midway between the lower rib margin and the iliac crest. Hip circumference will be measured at the widest part of your buttocks. Body mass index (BMI) is calculated as weight (kg) divided by the square of height (m). Blood pressure will be measured twice after each subject had been seated for 10 min using a mercury electric sphygmomanometer. The average will be used for analysis.
OGTT will be performed after overnight fasting, 30 min and 2 h after the intake of 75 g glucose for the assessment of serum insulin and glucose levels. The blood samples were frozen at −80 °C until assayed. Venous blood samples will be collected after fasting over 8 h at 7 ~ 8 a.m. for the measurement of triglyceride and total cholesterol, high-density lipoprotein and low-density lipoprotein, and LPS and GLP-1 levels.
Stool samples collection
The stool samples will be collected at the first visit and at months 6, 12, 18, 24. Detailed stool sample collection and transportation instructions will be given by a study researcher. We will provide to subjects the materials for sample collection and transportation from home to hospital which including: 1 cool box, 1 sterile dressing room, 1 sterile EP tubes, 1 pair of sterile tweezer, 1 pair of plastic gloves and a plastic bag. The participants are advised to sample approximately 5 g of feces by tweezer attached to the sterile EP tubes. Then the sterile EP tubes are stored in a plastic bag in the cool box. After samples are collected, the subjects will immediately deliver the samples to the clinical laboratory in 1 h.
The stool samples will be frozen at −80 °C after collected and the DNA extraction will be performed using the E.Z.N.A.® Stool DNA Kit (Omega Bio-tek, Norcross, GA, U.S.) according to manufacturer’s protocols. Fecal bacteria composition will be determined using 16S rRNA based methods and illumina MiSeq sequencing.
The administration of study drugs will be recorded. Compliance will be discussed at each study visit and assessed based on returned tablet counts. Patients will be asked to return all unused study products including empty packages to the clinic at each visit.
Sample size calculations
We will aim to recruit 100 subjects in each arm of the trial. Assuming a rate of 35 % developing diabetes in placebo group in China [20, 21], a type I error of 0.05 with two-sided, we have 80 % power to detect a 14 % difference in probiotics group at 2 year follow-up (accounting for our primary outcomes).
Considering a dropout rate of 10 %, the sample size for enrolled patients will rise up to 220 for all patients.
Participants are individually randomized to placebo or probiotics groups in a 1:1 allocation. Random number are generated by excel and overseen by an independent statistician. Research staff and participants remain blind to the allocated treatment group.
All analyses of end points are based on the intention-to-treat (ITT) principle. The results of the trial are reported as comparative summary statistics (difference in response rate or means) with 95 % confidence intervals. All statistical tests use a 5 % with two-sided significance level. Two-sided t-tests and chi-square tests are used to analyze the differences between the groups at baseline and during follow-up. For the primary outcome, survival curves are used to calculate the cumulative incidence of diabetes. The difference between the groups in the incidence of diabetes is tested by means of the two-sided log-rank test. For the secondary outcomes (the difference of the changes of blood glucose, lipid profile and insulin sensitivity, body weight, waist circumference, abundance of bacteria, levels of LPS and GLP-1 between the two groups), a mixed models are used on data collected at 6,12,18 and 24 months. An interaction between treatment group and time is fitted to allow estimation of treatment effects at each time point. The model adjusts for baseline variable and minimization factors. Linear Pearson’s correlation, partial correlation, and logistic regression analysis are used for analyzing relationships.
Reporting of adverse events for this trial
We will report adverse events that might be reasonably related to probiotics. Adverse events are collected from time of signature of informed consent throughout the treatment period.
Ethics, consent and permissions
The institutional review board of Shanghai East Hospital have reviewed and approved the protocol, ref: 2013–009. Trial procedures are compliant with the Declaration of Helsinki and the trial is registered with the Chinese Clinical Trials Register (ChiCTRTRC13004024). All subjects in this study are volunteers and complete a written informed form at the first visit. Each subject is given full and adequate oral and written information about the nature, purpose, possible risk and benefit of the study.
The present study will comply with the scientific ethics and integrity requirements in scientific and clinical practice.
Consent to publish
We have obtained consent to publish from the participant to report individual patient data.
IGT is associated with progressing to diabetes and risk of cardiovascular diseases. Epidemiological studies showed that 25 % of patients with IGT progress to type 2 diabetes in 5 years  and the rate reach to 41 % in China . An unhealthy diet and the alterations in gut microbiota play an important role in this process. Although the diet control is helpful to the prevention and treatment of diabetes, it is difficult for the individual to insist on. Recent studies showed that reshaping the gut microbiome can improve the energy metabolism [16–19, 22], which provide a new insight on preventing the occurrence of type 2 diabetes. Therefore, we present a design of a randomized double-blinded, placebo-controlled trial to investigate the efficacy and safety of probiotics intervention in preventing conversion of IGT to type 2 diabetes in China. To the best of our knowledge, this is the first study, in a relative larger sample and in a longer period, to evaluate the efficacy of probiotics administration on glucose metabolism in IGT subjects.
This trial has been designed to address the limitations of previous studies of the effects of probiotics administration on the outcomes of metabolic diseases. The duration of intervention and the sample size will allow us to explore the effects of probiotics intervention on metabolic diseases. We expect that the overall incidence of diabetes will be significantly reduced in probiotics group than placebo group, which suggest that type 2 diabetes can be prevented by oral administration probiotics for subjects at high risk for the disease. We also anticipate that probiotics intervention will improve insulin sensitivity, lipid profile, and inflammatory state by changing the gut microbiota composition.
This trial using oral administration of probiotics offers a new approach for both diabetes and metabolic diseases prevention. If the result of the research shown to be effective, it will open a new strategy for diabetes prevention.
Participant recruitment started in September 2014. Baseline measurement started in October 2014 for the first enrolled subjects. Medicine interventions started in October 2014. The recruitment of subjects is continuing until October 2015.
Probiotics prevention diabetes programme
Impaired glucose tolerance
Oral glucose tolerance test
National center for medical culture collections
Body mass index
Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310:948–59.
Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.
Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537–44.
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet. 2006;368:1096–105.
Gong QH, Kang JF, Ying YY, Li H, Zhang XH, Wu YH, et al. Lifestyle interventions for adults with impaired glucose tolerance: a systematic review and meta-analysis of the effects on glycemic control. Intern Med. 2015;54:303–10.
Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, et al. Prevention of type 2 diabetes with troglitazone in the diabetes prevention program. Diabetes. 2005;54:1150–6.
Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet. 2010;376:103–11.
Hu R, Li Y, Lv Q, Wu T, Tong N. Acarbose monotherapy and type 2 diabetes prevention in Eastern and Western Prediabetes: an ethnicity-specific meta-analysis. Clin Ther. 2015;37:1798–812.
Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101:15718–23.
Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027–31.
Karlsson FH, Tremaroli V, Nookaew I, Bergstrom G, Behre CJ, Fagerberg B, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498:99–103.
Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60.
Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, et al. Selective increases of bifidobacteria in gut microflra improves high-fat diet-induced diabetes through a mechanism associated with endotoxemia. Diabetologia. 2007;50:2374–83.
Wagnerberger S, Spruss A, Kanuri G, Stahl C, Schröder M, Vetter W, et al. Lactobacillus casei Shi-rota protects from fructose-induced liver steatosis: a mouse model. J Nutr Biochem. 2013;24:531–8.
Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition. 2012;28:539–43.
Shakeri H, Hadaegh H, Abedi F, Tajabadi-Ebrahimi M, Mazroii N, Ghandi Y, et al. Consumption of synbiotic bread decreases triacylglycerol and VLDL levels while increasing HDL levels in serum from patients with type-2 diabetes. Lipids. 2014;49:695–701.
Lindsay KL, Brennan L, Kennelly MA, Maguire OC, Smith T, Curran S, et al. Impact of probiotics in women with gestational diabetes mellitus on metabolic health: a randomized controlled trial. Am J Obstet Gynecol. 2015;212:496.e1-11.
Mahboobi S, Iraj B, Maghsoudi Z, Feizi A, Ghiasvand R, Askari G, et al. The effects of probiotic supplementation on markers of blood lipids, and blood pressure in patients with prediabetes: a randomized clinical trial. Int J Prev Med. 2014;5:1239–46.
Qian Q, Li X, Huang X, Fu M, Meng Z, Chen M, et al. Glucose metabolism among residents in Shanghai: natural outcome of a 5-year follow-up study. J Endocrinol Invest. 2012;35:453–8.
Lian F, Li G, Chen X, Wang X, Piao C, Wang J, et al. Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: a double-blind, randomized, placebo-controlled, multicenter trial. J Clin Endocrinol Metab. 2014;99:648–55.
Everard A, Matamoros S, Geurts L, Delzenne NM, Cani PD. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice. MBio. 2014;5:e01011–4.
This study is funded by the Research Program of Shanghai (134119a3300), Key Specialty Construction Project of Pudong Health and Family Planning Commission of Shanghai (Grant No. PWZz2013-04) and Project of Science and Technology of Pudong Health and Family Planning Commission of Shanghai (Grant No. PKJ2014-Y13).
We are grateful to the patients; physicians and nurses in the Department of endocrinology of Shanghai Easthopital for taking part in this trial. We are also grateful to Jun Liu from Shanghai Fifth People’s Hospital; Li Qin from Xinhua Hospital, Chongming Branch; Ligang Zhou from Shanghai Pudong Hospital; Xiaohua Li from Shanghai Seventh People’s Hospital, Shanghai, China.
The Probiotics Prevention Diabetes Programme has received financial support from governmental funding. Funding of RMB 300 thousand from the Science and Technology Commission of Shanghai Municipality (134119a3300) covers the cost of the study from June 2013–June 2016. Funding of RMB 170 thousand from the Project of Science and Technology of Pudong Health and Family Planning Commission of Shanghai (Grant No. PKJ2014-Y13) covers the programme delivery from October 2014 to October 2017. Further support from the Key Specialty Construction Project of Pudong Health and Family Planning Commission of Shanghai (Grant No. PWZz2013-04) provided RMB 300 thousand to cover the programme delivery and trial recruitment in community.
Bo Feng is the principal investigator (PI). He designed the study and will oversee the project implementation, train researchers and doctoral students, participating in data collection, analyses and interpretation and writing publications. Qun Yan and Xu Li participate in study design and will implement the designed protocol, participating in supervise students, data collection, data analyses and interpretation and writing publications. All authors read and approved the final manuscript.